pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.

The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs. These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metabolism, and elimination. The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aqueous solubility data generated from high throughput screening methodologies in drug discovery settings. The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class. The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa). Receiver operating characteristic (ROC) curve analysis was utilized to define the permeability class boundary. At permeability ≥ 5 × 10(-6) cm/s, the accuracy of predicting Fa of ≥ 0.90 was 87%. Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metabolism classes (BDDCS). The equilibrium solubility of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5). Although dose was not considered, good concordance of the measured solubility with BCS and BDDCS solubility class was achieved, when solubility at pH 1.2 was used for acidic compounds and FaSSIF solubility was used for basic, neutral, and zwitterionic compounds. Using a cutoff of 200 μg/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS solubility classes. In conclusion, this study identified pH-dependent permeability and solubility criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process. Additionally, such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.

[1]  Manfred Kansy,et al.  High throughput solubility measurement in drug discovery and development. , 2007, Advanced drug delivery reviews.

[2]  Marilyn E. Morris,et al.  Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships , 2009, The AAPS Journal.

[3]  Per Artursson,et al.  Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method , 2005 .

[4]  Viv Bewick,et al.  Statistics review 13: Receiver operating characteristic curves , 2004, Critical care.

[5]  Vinod Nair,et al.  Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. , 2004, Current drug metabolism.

[6]  F. Russel,et al.  Mechanisms and clinical implications of renal drug excretion* , 2001, Drug metabolism reviews.

[7]  Jochem Alsenz,et al.  Development of a partially automated solubility screening (PASS) assay for early drug development. , 2007, Journal of pharmaceutical sciences.

[8]  Hans Lennernäs,et al.  Comparison Between Permeability Coefficients in Rat and Human Jejunum , 1996, Pharmaceutical Research.

[9]  Sean Ekins,et al.  Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties , 2010, Drug Metabolism and Disposition.

[10]  Vinod P. Shah,et al.  Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.

[11]  Vinod P. Shah,et al.  The Use of BDDCS in Classifying the Permeability of Marketed Drugs , 2008, Pharmaceutical Research.

[12]  Tudor I. Oprea,et al.  BDDCS Applied to Over 900 Drugs , 2011, The AAPS Journal.

[13]  C. Bevan,et al.  A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.

[14]  M. Varma,et al.  Targeting intestinal transporters for optimizing oral drug absorption. , 2010, Current drug metabolism.

[15]  R Scott Obach,et al.  Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. , 2010, Journal of medicinal chemistry.

[16]  Nigel Greene,et al.  Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.

[17]  M. Varma,et al.  Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. , 2005, Journal of pharmaceutical sciences.

[18]  S. Wright,et al.  The molecular and cellular physiology of basolateral organic anion transport in mammalian renal tubules. , 2003, Biochimica et biophysica acta.

[19]  Lawrence X. Yu,et al.  The BCS, BDDCS, and Regulatory Guidances , 2011, Pharmaceutical Research.

[20]  M. Machida,et al.  Biopharmaceutics Classification by High Throughput Solubility Assay and PAMPA , 2004, Drug development and industrial pharmacy.

[21]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[22]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport. , 2001, Advanced drug delivery reviews.

[23]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[24]  Li Di,et al.  Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.

[25]  S. Stegemann,et al.  When poor solubility becomes an issue: from early stage to proof of concept. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  A. Avdeef,et al.  Physicochemical profiling (solubility, permeability and charge state). , 2001, Current topics in medicinal chemistry.

[27]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[28]  Lawrence X. Yu,et al.  High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. , 2010, Molecular pharmaceutics.

[29]  B. Feng,et al.  Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state , 2010, Expert opinion on drug metabolism & toxicology.

[30]  Alex Avdeef,et al.  The rise of PAMPA , 2005, Expert opinion on drug metabolism & toxicology.

[31]  Hatsuo Aoki,et al.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. , 1987 .

[32]  Kristina Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .

[33]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[34]  H Lennernäs,et al.  Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.

[35]  R. Obach,et al.  Physicochemical determinants of human renal clearance. , 2009, Journal of medicinal chemistry.

[36]  Pär Matsson,et al.  Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. , 2011, Journal of medicinal chemistry.

[37]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[38]  H Lennernäs,et al.  Intestinal permeability and its relevance for absorption and elimination , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[40]  S. Gattani,et al.  Solubility Enhancement of Lovastatin by Modified Locust Bean Gum Using Solid Dispersion Techniques , 2008, AAPS PharmSciTech.

[41]  Hans Lennernäs,et al.  Jejunal Absorption and Metabolism of R/S-Verapamil in Humans , 1998, Pharmaceutical Research.

[42]  B. Feng,et al.  Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion , 2012, Drug Metabolism and Disposition.

[43]  J. Denollet,et al.  Sensitivity and specificity of observer and self-report questionnaires in major and minor depression following myocardial infarction. , 2001, Psychosomatics.

[44]  J. Legendre,et al.  Determination of the Aqueous Solubility of Drugs Using a Convenient 96-Well Plate-Based Assay , 2001, Drug development and industrial pharmacy.

[45]  Leslie Z Benet,et al.  Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. , 2008, Advanced drug delivery reviews.